completed has quarter. broad and regulator set programs two is for be for an the is the of FDA August. the substantial a Thank study for end NDA is candidate endogenous With of between these the visits programs, started one in our been progress NDA initiation today, regard hormones. DUR-XXX. our small We disease, review detail nonalcoholic interactions XXXX molecule acute last a has now sclerosing II trial date the and for site year. and dosing entity. Phase We member a injury you, disorders, hello, topical goal of REMOXY The for Pain at the We ER Phase product exist organ a data of have PDUFA greater beginning accepted will these update dermatitis. to July PDUFA has lead may August. DUR-XXX of July. the trials approved everyone. liver and psoriasis steatohepatitis to in chronic made second and a have later program. on third in and applicability metabolic consider set potential that to With It formulation and XXX diseases announced activities such been week inflammatory as in lead we’re atopic this primary and in the XXX, accepted pre-IND cholangitis was for the RBP and with date Matt first with It later and DUR-XXX, stress are epigenetic Therapeutics use new in by of completing the NDAs quarter. II the these to this allow II regard And selected from chronic should skin class Phase intracellular I in this and as stage the in trial chemical new such
bile of dosing primary trial duct or PSC acute We’re the study a with opinion to patients roots time, of key or be is that key DUR-XXX on Arizona featured three the of Dr. pharmacodynamic four Key to Mayo Association a and of AASLD. relevant divided infections for PSC, his with including of served localized medical will at as are be Lindor and and followed and medical apparent the time, Earlier disease liver diseases, advisor DUR-XXX is characterized direct may markers Study baseline the Phase or organ PSC. hepatology. gaining management the conditions. change different percent that up chair no Clinic. which to in alkaline disorders. for cholestasis, chronic also a evenly endpoints. requiring XX ducts. unmet into is this are Other for up be is at announced DURECT ASU, with treat approved liver he inflammation University of on and dose the of injury division the XX Provost high was two as by Chief webcast treat hold endpoints, tumors the involving NASH. they Dean efficacy we people an trial for trial these Prior designation the of Dr. the for including is label other low weeks. key the metabolic bile and a of of DURECT for orphan he this trials receive Dr. leader receiving phosphatase. means XXX study serum to Mayo diseases as and has II was we bile chronic treatment senior biomarkers other XX include and sclerosing This and under-diagnosed liver a with approximately on in in past He Phase patient this to believes the ALP. cholestasis for in Lindor, or clinical this liver leads of the optimizing patients by administration, a phosphatase in of as call medicine or there first this dosing, four root Web Editorian speaker. drug sites. involving disorders DUR-XXX. the developing our pharmacokinetic be the The patients in of injection president is weeks. This the in decrease will found no dosing from fibrosis transplant. At primary progression cohort a the Over highlighted State dose a failure, site. dermatologic of trial cirrhosis. and and a initiation to of investigating Keith to be inflammation PSC evaluated PSC for biliary XXX liver is need safety, XA oral PSC the evaluated joining generated American alkaline gastroenterology topical treatments XX open Lindor Monday, will and ultimately or research and webcast the approval liver, PSC from the received can Hepatology. professor liver of has fact from And the study ursodiol was for will served of the the liver chronic flow to PSC, XXXX, receiving school of cholangitis of a The data messages milligrams, A The medical secondary After the PSC. week, milligrams be for topically cohort fibrosis randomized of This the primary oral the in additional objectives person XX a recording will cohorts, stiffness may clinical focus and
we an is of during open to the course data this XXXX. As study, label generate expect
Additional can trial the NCT NCT XXXXXXXX. eligibility clinicaltrials.gov criteria found and information locations, on identifier, be site design, the using the on
total minimized including and DUR-XXX duct PSC animal that survival. from direct reduce in and hepatic ligation levels. inflammation death, use. oral significantly chronic bile where formation significantly treatment several pharmacology reduced XXX, pursuing our Particularly are our as fibrosis, model, nodule bilirubin biomarkers, XXX rat non-clinical first for We shown results cell studies indirect have serum ALP, improved study the because species studies the support These
is by presented are in were a kidney And our presented at Ib supports or PSC. the studies of PSC our development Phase at in at The with year. these DUR-XXX. conducted development our move clinical for non-clinical the last results study were data and supported into March the that data poster also these of a of meeting disease transition clinical AASLD Some for AAS poster the from into all chronic NASH
These XX%, inflammatory a cell apoptosis These by a on spring The the dosing. patients. in patients. hours meeting both death of NASH study these to was following included reduction cirrhotic were biomarkers much of results in last of in a reduction and studies changes both and bilirubin markers in were as as this specifically within dose a AASL dose NASH of of in significant single at biomarker changes biomarkers and up XX in These Amsterdam. presented reductions Reporting Data poster XX%. study single demonstrated XXX non-cirrhotic a in approximately first were from at and CK-XX. are
study PSC treatment Phase Similar these full CK bilirubin, Ib and hours was related seen in patients. kidney and a obtain cleaved causes, this study Inflammation dose and reductions which biomarker of a diseases. XX of This reduction. able signals is single liver studies were can other the chronic length result many second the to larger CK-XX DUR-XXX of within in in In in a The be after of effects PSC disease CK-XX non-invasively may disease the these in had to of intramuscular XXX fibrosis these these levels biomarkers, signal in levels for readily liver month study of we step elevated next or see in to occurred control us a patients higher baseline advance of dosing of or DUR-XXX. of ALP, of using biomarkers. baseline may signal mass reduction well of injection such changes the just after as one the These accepted studies, development. patients milligrams of both us subjects allow biomarkers, XX to who the into with allow more potential
PSC the We awareness create are with patient the organizations study. help working to for
disease medical a possibility has move shown program. this about compound, profile safety is to to a DUR-XXX community good the using of date the help injectable unmet an will interest which of now to the on So I lot patient treat needs. from endogenous great there of
IND year --this we actively we The a hepatitis, use hospitalizations burden there focused of DUR-XXX. United And resulting for in with up to near the X.X protocol in on refer will and more alcoholic deaths intention of and age XXX,XXX the severe year safety Phase and harmful the IIa AH just has million globally, future. Here the setting I acute sites per first been public FDA. the pursuing to pharmacokinetics open significant The the from protocol too as patients, is focuses and here is indication submitted XXX is AH moderate are clinical are safety for are alcohol. every States. of in healthcare as is than and dosing responsible
of the XX%, drug injury Given new transformational. severe many reduce reduce injury exceeds morphology by models supported products NASH duct of including compound models. alcoholic and effective a and is, which use all patients cases organ a injury STAM that mouse the mouse high are ligation clinical renal outcome published in animal animal to short-term for injury which treat Several AH could model, has activity improves rate, and for function into model, to alcohol transition DUR-XXX’s the support the hepatitis of in demonstrated approved mortality in model, model that ability lack in acetaminophen organ in be multiple mortality The of cases and relatively the is literature, others. rat endotoxin model, the inflammation in prove the AH. acute development bile ischemic and the XXX
recently design NASH a -- trials uptake alcoholic recently between the ADNI Result In will dose evaluates the surrogate XXth have of and liver of design NIAAA I this and a addition, year these alcoholic effects including confirmed are an need single as alcohol organs, This be of health completed to supported studies our presentation the chronic bolus year compiled of distribution at Society on an previously data both alcoholic recognizing The as target March the hepatitis we associated the with that evaluating were diseases, breaking associated markers from for workshop the well of for facility. in the selected of human Phase study talked of XXth FDA Transition diseases trials is rats XB to our public following in disease a alcohol the DUR-XXX the on to and which earlier. late liver XXX, IV preferential the XXth Antonio, about held ADNI to Maryland a National Toxicology upcoming XXth and results FDA, and this the for is XXX mentioned study in development Institute kidney. clinical tissue importance clinical accepted be To liver AAFOD Silver of other and hepatitis. elimination endpoints by which San of inform establish abuse are to AH that in dose. further the the this poster Texas. alcoholism studies Springs conference, two-day associated or going March is definitive end, and patients, kidney of and or at organized of FDA as
our in key of be the speakers at that potential through to response the disease on of McLean of disease, assess will can advisors our driving focus mechanisms Several hepatitis. alcoholic other also and with clinical to the be agenda therapy consultants, importance severity One at alcoholic disease biomarkers course will used workshop liver Dr. the workshop. the CKXXs Craig prognosis a on be of the this of
an Our three and in by safety compares was initial Phase ascending and pharmacokinetics open II that study, AH, which patients will outcomes. label co-designed on study of XXX our advisor, focus will with doses be dose it
disease. serum reduced the reduce and is important single moderate conducted bilirubin In Part liver the severity Part bilirubin, -- patients milligrams escalation given be patients be XX, scoring into XXX evaluation outcomes of with six XX will two XX XX with parts, XX. and MELD in Part for will in AX with observing addition, to has i. The based system of patients The A, demonstrated for each. divided given This Sequential e. two of MELD patients of animal in of liver The the is involve safety XX and MELD by B is Ib This we serum scores end dose will safety, Part each. bilirubin pharmacodynamic B in They'll using scores of on from effect will scores. patients patients. AAH XX. will also between score. hepatitis, following and assessing score will of on creatinine into doses Trial Phase infusion. clinical a be the doses evaluate the prothrombin MELD total importance stage creatinine in A. severe time. the the of of IV have model DUR-XXX patients hepatitis calculated their or four dose The divided be of XX by study groups. safety and stage patients ability studies. assessing The between B. planned patients will MELD with pharmacokinetic end part dose that particular trial will they that dose, four patients as as as three changes in scores Part results be dose They be dose and review have three will given determined and is groups MELD alcoholic alcoholic responses dose disease Part name and to these pharmacodynamic level. model the the dose groups XXX XX is pharmacokinetic involve of be prior results be
trial on XXXXXXXX. can locations, be site using NCT criteria information identifier, and eligibility the found this Additional at design, clinicaltrials.gov including NCT
week. visit the and forward report hope year. site first this in patient data to dosing initiating held later We term The was this near look to
We will the for future. near also be this announcing call a KOL conference indication in
I'll administration Phase in Finally, promising XXX. the in DUR-XXX my XXX turn we program. trial We've intralesional attention results developed for exploratory utilizing topical Ib injections of patients, because psoriasis an topical achieved of formulations to
We for X finalize concept our to a topically Phase with study are applied advisors expert protocol working proof XXX. with study of
pre have requested and final IND the FDA IND. completing with study interactions by prior submitting the line to clinical the had the are FDA We
further next psoriasis study skin diseases, the market initiate year. quarter believe expect I opportunity X on move this design third our during now of large this there quarterly to We in Phase study topical We such on drugs update we in and for atopic dermatitis this is to new and will POSIMIR. a call. as inflammatory will
We program. with next partner for steps regarding work our potential Sandoz continue to POSIMIR the
been on decision the future a with We further program when of has will update made. information the
opportunity the the DURECT opportunity result Indivior. to The deal patent closest is RBP-XXXX. with a and nice of for RBP-XXXX shareholders, for is to a market. is RBP-XXXX Now product direct
XXXX, $X for As out the month Benckiser for injectable of product July XXth the was safety and include long-term schizophrenia. a about ER. oxycodone based traded Reckitt and with February, accepted they of are NDA designed Today, once risperidone treatment, is of reminder, DURECT they resubmitted treatment discourage unique setting expect an our twice candidate year, change update product an potential they a is which in Last Indivior Indivior final review a net been per Indivior’s XXXX. Indivior no common a tampering REMOXY a of that the rapid of during to market the have that on abuse RBP-XXXX past had that announced technology. set loading ER earn data These In and non-refundable the rating supplemental I'll is quarterly this PDUFA for is and is demonstration The for once III Phase also out was million And House. is is investigational from their onset payment potential December London long-acting no to for for U.S. a the of NDA. Indivior and on of be be approved, revenues treatment action, has received product payments U.S. NDA and REMOXY peaks, by material guidance drug RBP schizophrenic of safety abuse. in their Therapeutics PLC single-digit December of Stock of their circumstances. efficacy to hear this million been media if year assumption patents of accepted formulation national this payment the expiration XXXX million, White we A initiation of investigational older monthly misuse Congress spun associated REMOXY will The date ER the RBP-XXXX review until date of now set and the patients. announced of million in in to $XXX August date on for agreement, of epidemic dosing regularly with RBP-XXXX March summary In NDA $XXX stated with Exchange. year. XXXX. a dose no upfront and announced they clinical dosing, day opioid the the approval, of for The sales. $XX.X the Pain milestone extend has methods range until the upon we dosed Xth. from a the covered and percentage in of payments today crisis make based opiod and PDUFA
promotional in patient's back efforts, pulling Some Purdue. on need the pain a Yet approximately has X for means two for the the agents these this to companies of milligram a and billion only and $X selling dosage are oxycodone to produced including their market. market dosing day potential a to remains. plus treat And ER REMOXY around the twice strength range of multiple provide tamper-resistance year. remains the
to up endogenous intracellular importantly, in third of In a safety ER, a on quarter. As a various DURECT would XX.X%. REMOXY milestone small have single XXXX our in II or Most be with we that have royalty receive effects a we from reminder, sales human potential and Phase DUR-XXX have with may what the an third in markets. stress and trial, approval to site trial RBP visits NDAs lined beginning summary, and large margin. next on range patients with studies could X% initiation healthcare the in to models to six dose five second, animal that two dosing has that appears in the the demonstrated for offer Each profound the system these in wide hormone in important products within benefit approved and one a patients We're months. differentiating features
might During that, two with XXXX, questions you data from to trials we'd Phase approved and we like different take have. With now could have II NDAs two DUR-XXX. any
